Balchem Co. (NASDAQ:BCPC - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Balchem in a report issued on Monday, February 24th. HC Wainwright analyst R. Selvaraju now anticipates that the basic materials company will post earnings of $0.99 per share for the quarter, down from their previous estimate of $1.06. HC Wainwright has a "Buy" rating and a $190.00 price target on the stock. The consensus estimate for Balchem's current full-year earnings is $4.64 per share. HC Wainwright also issued estimates for Balchem's Q2 2025 earnings at $1.03 EPS, Q3 2025 earnings at $1.08 EPS, Q4 2025 earnings at $1.12 EPS, FY2025 earnings at $4.22 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.17 EPS, Q3 2026 earnings at $1.20 EPS and FY2026 earnings at $4.71 EPS.
Several other research analysts also recently commented on BCPC. Sidoti raised Balchem to a "hold" rating in a research report on Tuesday. StockNews.com downgraded Balchem from a "buy" rating to a "hold" rating in a research report on Tuesday.
Read Our Latest Report on BCPC
Balchem Stock Performance
BCPC traded up $2.03 on Wednesday, hitting $174.03. The company had a trading volume of 134,481 shares, compared to its average volume of 131,741. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. The company's fifty day moving average price is $162.41 and its 200 day moving average price is $169.56. The stock has a market cap of $5.66 billion, a price-to-earnings ratio of 44.28, a price-to-earnings-growth ratio of 4.41 and a beta of 0.69. Balchem has a 1-year low of $137.69 and a 1-year high of $186.03.
Balchem (NASDAQ:BCPC - Get Free Report) last posted its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The company had revenue of $240.00 million during the quarter, compared to analyst estimates of $239.96 million.
Balchem Increases Dividend
The company also recently disclosed an annual dividend, which was paid on Friday, January 17th. Stockholders of record on Thursday, December 26th were given a dividend of $0.87 per share. The ex-dividend date of this dividend was Thursday, December 26th. This is a boost from Balchem's previous annual dividend of $0.79. This represents a dividend yield of 0.4%. Balchem's payout ratio is currently 22.14%.
Institutional Trading of Balchem
Institutional investors and hedge funds have recently modified their holdings of the company. Watts Gwilliam & Co. LLC increased its position in shares of Balchem by 63.7% during the fourth quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company's stock valued at $5,438,000 after purchasing an additional 13,642 shares during the period. JPMorgan Chase & Co. grew its position in Balchem by 1.7% in the third quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company's stock valued at $80,782,000 after acquiring an additional 7,721 shares during the period. Stifel Financial Corp grew its position in Balchem by 26.2% in the third quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company's stock valued at $2,093,000 after acquiring an additional 2,467 shares during the period. Apollon Wealth Management LLC bought a new stake in Balchem in the fourth quarter valued at $503,000. Finally, Congress Asset Management Co. grew its position in Balchem by 5.4% in the fourth quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company's stock valued at $51,769,000 after acquiring an additional 16,170 shares during the period. 87.91% of the stock is currently owned by institutional investors.
About Balchem
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
